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Enabling Technologies for Cell-Based Clinical Translation
Survival and Functionality of Human Induced
Pluripotent Stem Cell-Derived Oligodendrocytes in a
Nonhuman Primate Model for Multiple Sclerosis
ARUN THIRUVALLUVAN,a MARCIN CZEPIEL,a YOLANDA A. KAP,c IETJE MANTINGH-OTTER,a
ILIA VAINCHTEIN,a JEROEN KUIPERS,b MARJOLEIN BIJLARD,b WIA BARON,b BEN GIEPMANS,b
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ABSTRACT
Fast remyelination by endogenous oligodendrocyte precursor cells (OPCs) is essential to prevent ax-
onal and subsequent retrograde neuronal degeneration in demyelinating lesions inmultiple sclerosis
(MS). In chronic lesions, however, the remyelination capacity of OPCs becomes insufficient. Cell ther-
apy with exogenous remyelinating cells may be a strategy to replace the failing endogenous OPCs.
Here, we differentiated human induced pluripotent stem cells (hiPSCs) into OPCs and validated their
proper functionality in vitro as well as in vivo inmousemodels forMS. Next, we intracerebrally injected
hiPSC-derivedOPCs inanonhumanprimate (marmoset)model forprogressiveMS; thegraftedOPCs spe-
cifically migrated toward the MS-like lesions in the corpus callosum where they myelinated denuded
axons. hiPSC-derived OPCs may become the first therapeutic tool to address demyelination and neurode-
generation in the progressive forms of MS. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1550–1561
SIGNIFICANCE
This study demonstrates for the first time that human induced pluripotent stem cell (iPSC)-derived
oligodendrocyte precursor cells (OPCs), after intracortical implantation in a nonhuman primate
model for progressivemultiple sclerosis (MS),migrate to the lesions and remyelinate denuded axons.
These findings imply that human iPSC-OPCs can be a therapeutic tool for MS. The results of this fea-
sibility study on the potential use of hiPSC-derived OPCs are of great importance for all MS re-
searchers focusing on the stimulation of remyelination in MS patients. Further optimization and
research on practical issues related to the safe production and administration of iPSC-derived cell
grafts will likely lead to a first clinical trial in a small group of secondary progressiveMS patients. This
would be the first specific therapeutic approach aimed at restoringmyelination and rescuing axons in
MS patients, since there is no treatment available for this most debilitating aspect of MS.
INTRODUCTION
Multiple sclerosis (MS) is a devastating disease of
the central nervous system (CNS) characterized by
inflammation, loss of myelin, axonal and neuronal
degeneration, and progressive brain atrophy [1].
MS is generally consideredanautoimmunedisease,
manifesting itself in most patients by a relapsing-
remitting course (RRMS) [2]. During the relapse
phase of RRMS, autoreactive T cells invade the
CNS and trigger myelin degradation and oligoden-
drocyte death. During the remission phase, much
of the myelin damage is restored by endogenous
oligodendrocyte precursor cells (OPCs). New in-
sights tend to consider MS as a continuously pro-
gressing, neurodegenerative disorder, over which
a fluctuating aberrant autoimmune response is
superimposed. The relapses do not affect the un-
derlying continuation of neurodegeneration, which
becomes overt again in the relapse-free secondary
progressive state [3]. In line with this view is the ob-
servation thatmanynovel potent anti-inflammatory
drugs can delay or even eliminate relapses in RRMS
but are still unable to stop the transition to the sec-
ondary progressive phase. In this novel perspective
onMS, primary progressive MS, lacking inflamma-
tory relapses, is the “purest” form of the disorder
[3]. In the (secondary) progressive phase, which
typicallydevelopsatanadvancedage,endogenous
OPCs are no longer able to restore myelin to pre-
vent neurodegeneration and, with that, loss of
neurological function. Novel therapies for chronic
progressive types of MS should focus on arresting
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ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL
TRANSLATION
with themosteffectiveprotectionofferedby rapidaxonal remyelina-
tion. Cell-based remyelination therapy has been considered a valid
approach [4]. Several sources for exogenous, transplantable OPCs
have been proposed; oligodendrocyte precursors have been gener-
ated from neural stem cells (NSCs) [5] and embryonic stem cells
(ESCs). Thepotential clinical applicationofbothcell types inMS,how-
ever, is problematic. Sources of NSCs are difficult to access, andNSCs
appear to be restricted in their proliferation and differentiation po-
tential, whereas the use of ESCs raises ethical concerns. Moreover,
OPCs derived from both of these nonautologous cell sources would
be attackedby the host immune systemand inevitably rejected after
implantation. A therapyusing these cellswouldneed tobeaccompa-
nied by immunosuppressive treatment.
In2006, thephenomenonof inducedpluripotencywas first de-
scribed [6]. Lacking the disadvantages of NSCs and ESCs, induced
pluripotent stem cells (iPSCs) have become intensively studied
as a potential, novel source of patient-specific cell types for disease
modeling and autologous cell-based therapies. A few studies have
demonstrated that human iPSCs can be differentiated into OPCs
and produce myelin basic protein (MBP) [7–11]. The functionality
and clinical potential of these human iPSC-derived OPCs were
proven after transplantation in a rat model for optic nerve demy-
elination [8] and in newborn shiverer mice [9, 10]. Moreover, hu-
man iPSC-derived OPCs grafted into irradiated rats appeared to be
effective in restoring myelin damage caused by radiation [12].
Noneof theanimalmodels above represents theautoimmunecon-
dition of the inflammatory-demyelinated lesion in MS [13].
In the present study, we examined for the first time the fate
and functionality of human iPSC-derived OPCs after implantation
in anonhumanprimatemodel ofMS.After verifying thevalidity of
our human iPSC-OPC differentiation protocol and the functional-
ity of these OPCs in vitro and in vivo in two mouse models,
we stereotactically injected suspensions of human iPSC (hiPSC)-
derived OPCs into the cerebral cortex of marmosets with exper-
imental autoimmuneencephalomyelitis (EAE).We inducedEAE in
themarmosetmonkeys by immunizationwith a synthetic peptide
representing residues 34 to 56 of humanmyelin oligodendrocyte
glycoprotein (MOG34–56) [14]. This specific primate EAE model is
considered the best animalmodel ofMS, as it approximates progres-
sive disease in clinical and pathological presentation. Important for
the present study is the occurrence of typical demyelinated, inflam-
matory lesions resembling those found in the brains of MS patients.
We demonstrate that implanted human iPSC-derived OPCs survive
and migrate toward MS-like lesions in the corpus callosum, where
they differentiate into myelin-forming mature oligodendrocytes.
MATERIALS AND METHODS
Differentiation of hiPSCs Toward Oligodendrocytes
For thedifferentiationofhiPSCs intooligodendrocytes, a five-stage
protocol was developed: (a) generation of primitive neuroepithe-
lial cells, (b) specification ofOlig2 progenitor cells, (c) generation of
pre-OPCs, (d) maturation of pre-OPCs to OPCs, and (e) differentia-
tion ofOPCs on substrate. A detailed description of the various cul-
ture conditions for each stage may be found in the supplemental
online data.
At defined time points (e.g., every 2weeks) some of the float-
ing hiPSC-derived spheres were seeded onto coverslips coated
with polyornithine/laminin (20 mg/ml) to check for the identity
of the cells migrating out of the cell clusters. At this stage, cells
were cultured in the medium described for Stage 4. The number
ofOPCsmigrating out typically increased over time; on average, it
took around140–150days to complete theprotocol, resulting in a
cell population of OPCs with a purity of 75% as determined by im-
munohistochemistry (almost all other cells being NSCs). From
each stage, cells were fixed with 4% PFA and immunocytochem-
ically stained to verify cell identity and control the differentiation
progress.
Cocultures of hiPSC-Derived OPCs and Dorsal Root
Ganglion Neurons
To examine the myelinating capacity of hiPSC-derived OPCs
in vitro, they were cocultured with rat dorsal root ganglion
(DRG) neurons. DRG neurons were dissected from 15-day-old
Wistar rat embryos and digested in papain (1.2 U/ml; Sigma-
Aldrich, St Louis, MO, http://www.sigmaaldrich.com), L-cysteine
(0.24mg/ml; Sigma-Aldrich), andDNase I (40mg/ml; Roche, Basel,
Switzerland, http://www.roche.com) for 1 hour at 37°C. The dis-
sociated cells were plated at a density of 60,000 cells per 13-mm
coverslip precoated with 5mg/ml polylysine/laminin andMatri-
gel Growth Factor Reduced (1:40 dilution). DRG neurons were
cultured for 21 days in Dulbecco’s modified Eagle’s medium
(Thermo Fisher Scientific Life Sciences, Waltham, MA, http://
www.thermofisher.com) supplemented with 10% fetal calf serum
(FCS) (Bodinco, Alkmaar, The Netherlands, http://www.bodinco.nl;
L-glutamine) and penicillin/streptomycin in the presence of nerve
growth factor (100 ng/ml). Cells were pulsed four times for 2 days
with fluorodeoxyuridine (10 mM) to remove contaminating prolif-
erating cells, in particular fibroblasts and Schwann cells. The purity
of the DRG culture was microscopically confirmed. Subsequently,
approximately 25,000 hiPSC-derived OPCs were seeded onto
coverslips containing the DRG neurons with extensive axonal out-
growth. The following day, the medium was changed to glia me-
dium without platelet-derived growth factor AA (PDGF-AA).
OPCswere coculturedwith the DRG neurons for 28 days, withme-
dium change every second day. After that period, cultures were
fixed with 4% paraformaldehyde (PFA) and immunostained for
MBP and neurofilament (NF).
EAE Induction in the Common Marmoset
Four adult (female, age 2–5 years) commonmarmosets (Callithrix
jacchus) were obtained from the purpose-bred colony at the Bio-
medical Primate Research Centre (Rijswijk, The Netherlands).
Only marmosets that were declared healthy after the veterinar-
ian’s physical, hematologic, and biochemical check-up were in-
cluded in the study. Monkeys were pair-housed in spacious
cages and remained under intensive veterinary supervision
throughout the study. Thedaily diet consistedof commercial food
pellets for New World monkeys (Special Diet Services, Witham,
Essex,UK, http://www.sdsdiets.com), supplementedwith raisins,
peanuts, marshmallows, biscuits, and fresh fruit. Drinking water
was provided ad libitum.
All experimental procedures were reviewed and approved by
the Institute’s Animal Ethics Committee, and animals were housed
and handled according to Dutch Law in animal experimentation.
The animal facilities of the Biomedical Primate Research Centre
havebeen inspected and accreditedbyAssociation for Assessment
and Accreditation of Laboratory Animal Care International. EAE in
marmosets was induced with a synthetic peptide representing
amino acids 34–56 of humanmyelin oligodendrocyte glycoprotein
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(MOG34–56; sequence = GMEVGWYRPPFSRVVHLYRNGKD; Cam-
bridge Research Biochemicals Limited, Cleveland, UK, http://www.
crbdiscovery.com) emulsified in incomplete Freund’s adjuvant
(IFA) (BD, Detroit, MI, http://www.bd.com). The inoculum con-
tained 100 mg MOG34–56 in 200 ml phosphate-buffered saline
(PBS) andwas emulsified in 200ml IFA by gentle stirring for at least
1 hour at 4°C. The emulsion was injected as 4 spots of 100 ml into
the dorsal skin, 2 in the axillary and 2 in inguinal region under se-
dationbyalfaxalone (10mg/kgalfaxan;Vetoquinol,DenBosch,The
Netherlands, http://www.vetoquinol.nl), with booster immuniza-
tions occurring every 28 daysuntil development of overt neurolog-
ical disease (EAE score $ 2) was observed. Clinical signs were
scored daily by two independent observers using a previously de-
scribed semiquantitative scale [15]. Briefly, 0 = no clinical signs;
0.5 = apathy, altered walking pattern without ataxia; 1 = lethargy,
tail paralysis, tremor; 2 = ataxia, optic disease; 2.25 =monoparesis;
2.5 = paraparesis, sensory loss; 3 = para- or hemiplegia. Overt neu-
rological deficit starts at score 2. For ethical reasons,monkeyswere
sacrificed once paresis of one or more limbs (score $ 2.5) was ob-
served. Bodyweightmeasurementsof consciousmonkeys,which is
used a surrogate diseasemarker, were performed twice per week).
Stereotactic Procedure in the Common Marmoset
hiPSC-derived OPCs were injected above the corpus callosum
of marmosets via a stereotactic procedure 79 days after im-
munization. Animals were sedated by alfaxan and received
buprenorphine (Buprecare, 0.3 mg/ml buprenorphine base,
20–100 mg/kg; Schering-Plough, Maarssen, The Netherlands,
http://www.schering-plough.com) as analgesic. Differentiated
hiPSC-derived OPCs were transfected with episomal green fluores-
cent protein (GFP) (pCXLE-EGFP) for 4–6hourswith FuGENEHDand
refreshed with OPCmedium. Episomal GFP-labeled hiPSC-derived-
OPCsweregentlydetached fromthesubstrateusingAccutase, spun
down,and resuspended inPBSataconcentrationof12,500cellsper
microliter, and 4 ml of cell suspension was stereotactically injected
using the following coordinates in relation to the bregma: anterior-
posterior, 3.8; lateral, 2.5; vertical, 8; 20-degree angle, 16. Injection
speed was kept at 2 ml of cell suspension per minute followed by
5 minutes of deposition time before needle retraction. To prevent
immune rejection of the xenografts, themarmosets received cyclo-
sporine A (Sandimmune, Novartis, Basel, Switzerland, http://www.
novartis.com) once daily by intramuscular injection of 10 mg/kg,
starting 1 day before the stereotactic procedure.
To follow the fate (survival, migration, and differentiation) of
the graftedOPCs, we planned to perfuse and fixate themarmosets
with 4% PFA under alfaxan and ketamine anesthesia at four time
points after implantation: 10, 20, 30, or 40 days. Ethical restrictions
did not allow us to follow EAE-affected marmosets for more than
40 days. Brain and spinal cord were stored in formalin for 2 weeks
andthen transferred intoPBS, further sectioned(16-mmcryosections),
and prepared for immunohistochemical and histological analysis.
Immunochemistry
PFA-fixed cells or tissue slices were washed two times with PBS.
Nonspecific antibody binding sites were blocked with PBS+ (PBS
containing 0.1% Triton X-100) with 5% normal goat serum (NGS)
and 2% FCS for 1 hour at room temperature. Subsequent incuba-
tion with primary antibodies diluted in PBS+ with 1%NGS and 1%
FSCwasperformedovernight at 4°C.After extensivewashingwith
PBS, cells/tissues were incubated with appropriate secondary
antibodies and Hoechst for 1 hour at room temperature, washed
with PBS, and mounted on glass slides. The following primary an-
tibodieswere used, directed against OCT4 (sc-5279; Santa Cruz Bio-
technology, Santa Cruz, CA, http://www.scbt.com), SOX2 (#4900S;
Cell Signaling Technology, Danvers, MA, http://www.cellsignal.
com), NANOG (ab80892; Abcam, Cambridge, MA, http://www.
abcam.com), SSEA-4 (Hybridoma Bank, http://dshb.biology.uiowa.
edu;MC-813-70), TRA-1-60 (MAB4360;EMDMillipore,Billerica,MA,
http://www.emdmillipore.com), TRA-1-81 (sc-21706; Santa Cruz
Biotechnology),bIIItubulin (ab7751;Abcam),Desmin(M0760;Dako,
Carpinteria, CA, http://www.dako.com), GATA4 (sc-25310; Santa
Cruz Biotechnology), Nestin (MAB353; EMD Millipore), PAX6
(AB2237; EMD Millipore), OLIG2 (Tecan, http://www.tecan.com;
18953), NKX2.2 (Hybridoma Bank; 74.5A5), platelet-derived
growth factor receptor-a (PDGFRa) (sc-338; Santa Cruz Biotechnol-
ogy), NG2 (AB5320; EMDMillipore), myelin proteolipid protein (PLP)
(gift from the Department of Cell Biology University Medical Centre
Groningen),MBP (AB980; EMDMillipore), NF (EnCor Biotechnology,
Gainesville, FL, http://encorbio.com), CPCA-NF-H, hNuclei (MAB128;
EMD Millipore), NF (RT97 & 2H3; DSHB), IBA-1 (019-19741; Wako,
Osaka, Japan, http://www.wako-chem.co), CD11c (14-0114; eBio-
science, San Diego, CA, http://www.ebioscience.com), CD3 (eBio-
science; 14-0030), Ly-6C (MCA2389GA; AbD Serotec, Kidlington,
U.K., http://www.abdserotec.com), glial fibrillary acidic protein
(GFAP) (Z0334; Dako), GFP (MAB3580; EMD Millipore), Mac-2
(CL8942AP; Cedarlane Laboratories, Burlington, ON, Canada, http://
www.cedarlanelabs.com), Ki67 (ab15580; Abcam), and STEM121
(AB-121-U-050; StemCells, Newark, CA, http://www.stemcellsinc.
com). Tissue sections were also subjected to histochemical staining
such as Luxol fast blue and cresyl violet to visualizemyelin and gen-
eral tissue composition, respectively. Quantification of immune
cells in the EAE mice was done in standardized sections of multiple
animals (n = $ 4); quantification of implanted GFP-labeled hiPSC-
derived OPCs in the marmoset was done by counting the number
of positive cells in aminimumof five standard consecutive sections.
Electron Microscopy
Sectionswerepostfixedwith1%osmiumtetroxide in0.1Msodium
cacodylate for 2 hours at 4°C. The samples were washed with wa-
ter, dehydrated through an ethanol series (30, 50, 70, 100%), and
impregnated overnight in 1:1 Epon in ethanol. The diluted Epon
was replaced by pure Epon and refreshed three times. Sections
were embedded flat between two sheets of Aclar and polymerized
at 58°C. With a stereomicroscope, 1 3 1-mm areas representing
normal myelination, demyelination, and an implanted area were
cut out and glued on an Epon stub. Ultrathin sections (70 nm) were
cut using a LeicaUC7 ultramicrotome (Leica, Amsterdam, TheNeth-
erlands, http://www.leica-microsystems.com) and contrasted with
2% uranylacetate in methanol and Reynolds lead citrate (2 minutes
each). ImageswereacquiredwithaFEICm100transmissionelectron
microscope (FEI, Hillsboro, Oregon, http://www.fei.com) operated
at 80 KV equipped with aMorada digital camera (Olympus Soft Im-
aging Solutions,Mu¨nster, Germany, http://www.olympus-sis.com).
RESULTS
Generation and Characterization of PSCs
Weused skin fibroblasts from four healthy human donors to gen-
erate hiPSC lines. Fibroblast lines were transduced with a lentivi-
ral polycistronic construct encoding for Oct4, Sox2, Klf4, and
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fluorescent protein mCherry under the control of the EF1a pro-
moter [17]. The efficiency of lentiviral transduction (nearly
100%) and subsequent silencing of exogenous genes was defined
using an mCherry fluorescence marker. Of several emerging col-
onies, we picked two, further referred to in this paper as hiPSC
colony 1 (Col1) and hiPSC colony 2 (Col2), and expanded themun-
der feeder-free conditions.Weextensively testedwhether the se-
lected clones met the well-established pluripotency criteria (Fig.
1B). Picked colonies showed typical human ESC-like morphology
(Fig. 1B), expressed pluripotency-associated genes (Fig. 1B), and
were able to differentiate in vitro into derivatives of the three
germ layers (Fig. 1C). Moreover, we confirmed the pluripotency
of the reprogrammed cells with the teratoma formation assay af-
ter subcutaneous injection in NOD-SCID mice (Fig. 1C). We ob-
served no major differences between our two hiPSC lines (Col1
and Col2).
Differentiation of hiPSCs Into Oligodendrocytes
We differentiated the two hiPSC lines into oligodendrocytes
according to a modification of the protocol described for human
ESCs by Hu et al. [18] (Fig. 1D: see details in Materials and Meth-
ods). At first, pluripotent cellswere converted into embryoid bod-
ies (EBs) that started to develop into early neuroepithelial cell
clusters known as neural rosettes (Fig. 1D) after seeding on the
substrate in neural differentiation-promoting medium. At this
stage of differentiation, cells stained positive for the NSCmarkers
PAX6 and nestin (Fig. 1D). Individual neural rosette structures
were picked, mechanically dissociated, and cultured as suspen-
sion. At this stage, cell culture medium contained the growth fac-
tor bFGF and the morphogen SHH that allowed limited cell
proliferation and conversion of cells into pre-OPCs characterized
by the expression of the transcription factors OLIG2 and NKX2.2
(Fig. 1D).Maturationof pre-OPCs intoOPCswasachievedbywith-
drawal of SHH from the culturemediumand addition of a panel of
growth factors and morphogens such as PDGF-AA, IGF-1, NT-3,
and T3. At the end of this process, which lasted typically around
10 weeks, the formed oligospheres (clusters of OPCs) were
seeded on laminin substrate, allowing OPCs to migrate out of
the cell aggregates. Most of the migrating cells showed a typical
multipolarOPCmorphology (Fig. 1D) andweredouble-stained for
specific OPC markers such as PDGFRa/NKX2.2 and NG2/NKX2.2
(Fig. 1D). At this stage, the efficiency of differentiation was
assessed by counting double-positive PDGFRa/NKX2.2 cells.
The efficiency varied between the two hiPSC lines and typically
ranged from 45% (Col2) to 78% (Col1). Maturation of OPCs into
functional oligodendrocytes was achieved by culturing them for
another 2 to 3 weeks in growth factor-reduced conditions. OPCs
were indeedable todevelop intoMBP-andPLP-positiveoligoden-
drocytes (Fig. 1D); however, these highly specialized mature cells
require very specific culture conditions, and most of them do not
survive much beyond 3 weeks in the specific growth factor-
reduced medium.
Functionality of hiPSC-Derived OPCs In Vitro
To verify the proper differentiation and proper functionality of
hiPSC-derivedOPCs,we examinedmyelin formation in cocultures
of hiPSC-derived OPCs with rat DRG neurons. Four weeks after
plating, hiPSC-derived OPCs developed into mature, myelin-
producing oligodendrocytes (supplemental online Fig. 1A) with
a survival ratemuchhigher thanobserved inmonocultures lacking
DRG neurons. High-magnification images revealed extensive mye-
lination around the DRG axons, proving the myelin-forming capac-
ity of the hiPSC-derived oligodendrocytes (supplemental online
Fig. 1A).
Functionality of hiPSC-Derived OPCs In Vivo
To examine and verify the (re)myelinating capacity of hiPSC-
derived OPCs in vivo, we used the cuprizone mouse model. Mice
were fed a 0.2% cuprizone-containing diet for 6 weeks before
cell transplantation. Cuprizone causes selective oligodendrocyte
death and extensive demyelination, particularly in the corpus cal-
losum (supplemental online Fig. 1C); the bundles of nude axons in
the corpus callosum provide a proper in vivo environment to ex-
amine remyelination activity by implanted OPCs. Three weeks af-
ter stereotactic grafting of hiPSC-derived cells (at theOPC stageof
differentiation) (Fig. 1D) into the corpus callosum, animals were
sacrificed and tissue was analyzed for the survival and fate of the
implanted cells. Immunohistochemical staining of human nuclei
revealed the presence of implanted cells mainly within the area
of the corpus callosum (supplemental online Fig. 1D), traveling
along the axonal tracks for distances .1 mm from the injection
site. Double immunostaining and closer examination of the cell
fate revealed that the implanted cells started to express MBP
(supplemental online Fig. 1E). MBP/human nucleus double-
staining was typically prominent for hiPSC-derived OPCs that
migrated and settled along the axonal fibers of the corpus cal-
losum, obtaining a thin, elongated nucleus morphology, typical
for mature myelin-forming oligodendrocytes (supplemental online
Fig. 1E). Similar observations weremade after costaining for human
nuclei and NF (supplemental online Fig. 1F): implanted OPCs, no-
tably the ones with high migratory capacity that settled far from
the injection site, obtained a thin, elongated nuclear morphol-
ogy and became “squeezed in” between remyelinated axons
(supplemental online Fig. 1F). Such close proximity to axons is
one of the prerequisites for successful myelination. Part of the
implanted hiPSC-derived OPCs did not (yet) differentiate into
mature myelin-producing oligodendrocytes and retained OPC
characteristics such as PDGFRa expression and an OPC-typical
elongated, multipolar morphology (supplemental online Fig.
1F). The 3-week observation period may have been too short
for themtomigrate to their final destination and for furthermat-
uration. Finally, double staining for human nuclei and GFAP did
reveal a few differentiated astrocytes among the implanted
cells (supplemental online Fig. 1F). Quantification of implanted
human cells coexpressing MBP, PDGFRa, and GFAP revealed
that the majority of the implanted cells were oligodendrocytes
(supplemental online Fig. 1G).
In addition, we intended to validate the remyelinating capac-
ity of the hiPSC-derived OPCs in EAEmice, representing the auto-
immune inflammatory/demyelinating pathology of the chronic
progressive form of MS. Immunization with MOG-peptide com-
bined with complete Freund adjuvant results in the formation
of lesions in thebrainand the spinal cord,whichgive rise to clinical
symptoms of which the severity is indicated by the EAE score.
After intraventricular injection of the hiPSC-derived OPCs at the
earliest detectable clinical symptoms, we observed a significant
reduction of subsequent EAE scores in comparison with PBS-
injected control mice (supplemental online Fig. 2B). Histochemi-
cal analysis of theEAE lesions in the cerebellumatday36after EAE
induction revealed CD3+, CD11c+, and Ly6C+ cell infiltrates and
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demyelination (supplemental online Figs. 2E–2G, 3A). Comparing
the cerebellum lesions of the EAE mice that received hiPSC-
derivedOPCswith those in PBS-treated control EAEmice revealed
a significant reduction in cell infiltration in thehiPSC-derivedOPC-
treated mice (supplemental online Fig. 2E–2G). Iba-1 staining
showed fewer activated microglia/macrophages in the hiPSC-
Figure 1. Generationofhuman iPSCsandtheir differentiation towardOPCs. (A):Schematic representationof the study setup. (B):Generationand
characterization of hiPSC clones: phase-contrast image of hiPSC-colony, AP staining of hiPSC-colony, and RT-PCR analysis illustrating the endog-
enous expression of pluripotence-associated genes in reprogrammed cells; immunocytochemical detection of pluripotence-associated tran-
scription factors (OCT4, SOX2,NANOG) andmembranemarkers (SSEA4, TRA-1-60, TRA-1-81). Scale bars: 50mm; 500mmfor AP section. (C): In
vitro and in vivo spontaneousdifferentiationof hiPSCs. In vitro, hiPSCs differentiated via EBs into ectoderm (bIII-tubulin), endoderm (GATA4),
andmesoderm (Desmin). In vivo differentiation of hiPSCs toward teratomas: hematoxylin and eosin staining of teratoma sections reveals the
presence of neural, muscle, gland, and cartilage tissue. Scale bars: 50 mm; 200 mm for EB section. (D): Differentiation of hiPSCs into oligo-
dendrocytes. Simplified scheme of differentiation protocol. Neuroepithelium: neural rosettes containing NSCs expressing PAX6 and NESTIN;
pre-OPCs: immunostained for OLIG2 and NKX2.2; OPCs: phase-contrast image of OPCs migrating out of an oligosphere and (double) immu-
nostainings for PDGFRa/NKX2.2, NKX2.2/Hoechst, NG2/NKX2.2, andNKX2.2/Hoechst; oligodendrocytes:mature oligodendrocytes immuno-
stained for MBP and PLP. Scale bars: 50 mm. Efficiency of iPSC to OPC differentiation: expressed as percentage of PDGFRa/NKX2.2-positive
cells of the total number of cells in one culture dish at the end of differentiation (n = 3,6 SD) in two different hiPSC lines. Abbreviations: AP,
alkaline phosphatase; bFGF, basic fibroblast growth factor; EAE, experimental autoimmune encephalomyelitis; EB, embryoid body; GFP,
green fluorescent protein; hiPSC, human induced pluripotent stem cell; MBP, myelin basic protein; NSC, neural stem cell; OPC, oligoden-
drocyte precursor cell; PLP, myelin proteolipid protein; RA, rheumatoid arthritis; RT-PCR, reversetranscription-polymerase chain reaction.
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derived OPC-treated EAE mice compared with control PBS-
treated EAE mice (supplemental online Figs. 2E, 4C). Moreover,
the extent of demyelination was significantly less in the lesions
of hiPSC-derived OPC-treated mice in comparison with the con-
trol PBS-treatedmice (supplemental online Figs. 2C, 3), and fewer
endogenous PDGFRa-positive OPCs were present (supplemental
online Fig. 4A, 4B). Decreased demyelination, however, could not
be attributed to the activity of the implanted hiPSC-derived OPC,
because no exogenous (grafted) cells could be detected in the le-
sions. IVIS bioluminescence scans corroborated that most of the
grafted luciferase-labeled hiPSC-derived OPCs remained within
the ventricles (supplemental online Fig. 2D). The beneficial effect
of the grafted hiPSC-derivedOPCs on the extent of cell infiltration
anddemyelination, and thereforeon the resulting clinical score, is
most likely causedby secreted factors, in linewith previous obser-
vations that the beneficial effects of intraventricularly grafted
NSCs in EAE mice and primates [19, 20] and of NSCs in spinal
cord lesions [21] is mediated by secreted protective or anti-
inflammatory factors [22]. We compared the expression of the
most relevant secreted factors (suchasCXCL10,CNTF, IGF1,VEGF,
GDNF) by our hiPSC-derived OPCs with those of hiPSC-derived
NSCs and found a similar profile (supplemental online Fig. 5).
A major difference between hiPSC-derived OPCs and hiPSC-
derivedNSCswas thehigher expressionofhepatocyte growth fac-
tor, transforming growth factor-b, and interleukin-6 observed in
the hiPSC-derived OPCs.
Application of hiPSC-DerivedOPCs in theMarmoset EAE
Model for MS
After establishing the completeness of differentiation and proper
functionality of hiPSCs-derivedOPCs in vitro and in vivo,weexam-
ined the fate and functionality of hiPSCs-derived OPCs after ster-
eotactical injection into a nonhuman primate model for MS.
Immunization of unrelated commonmarmosets from an outbred
colony with recombinant MOG peptides 34–56 in incomplete
Freud’s adjuvant activates anewpathogenicmechanism that elic-
its pathological features reminiscent of progressiveMS, i.e., CD8+
T cell-mediateddemyelination inwhitematter, but also in cortical
graymatter of the brain and progressive loss of neurological func-
tions. The most prominent lesions containing severe demyelin-
ation and cell infiltration appear to be located within the corpus
callosum (Fig. 2; supplemental online Fig. 6A). In a first pilot study
(data not shown), we injected three EAE marmosets with hiPSC-
derivedOPCs into theCSF (cisternamagna) and sacrificed themon-
keys after 7 days. Although we did observe localization of viable
implanted cells in the ependymal cell layer that aligns the CSF,
the entrance of the implanted cells into the brain parenchyma
was slow and as yet minimal with this mode of administration.
In the present study, we implanted GFP-labeled hiPSC-derived
OPCs stereotactically near the medial line in the cortex just above
the corpus callosum at day 79 (Fig. 3A–3C). Daily immunosuppres-
sive treatmentwithcyclosporineAwasstarted justbefore injection
of the xenogenic grafts, to avoid interference with the develop-
ment of EAE. Initially, we had planned to sacrifice the marmosets
at 10, 20, 30, or 40 days after implantation. Unfortunately, the
10-day marmoset had to be sacrificed at day 3 for ethical reasons
because it reached paresis (EAE score 2.5) a few days after implan-
tation of the cells. Marmoset tissues were fixed and immunohisto-
chemically examined for the fate of the implanted hiPSC-derived
OPCs. Analysis of the GFP-labeled hiPSC-derived OPCs, at the
different time points of injection in the four different animals,
revealed the survival of these cells and their steadymigration from
the site of implantationmainly directed toward the large demyeli-
nated lesions in the corpus callosum (Fig. 3). The number of
implantedhiPSC-derivedOPCs thatcouldbedetected in the corpus
callosumafter cortical injection increased with time (Fig. 3C, 3E
and supplemental online Fig. 6B).
Migration across the corpus callosum occurred in both lateral
andanterior/posterior directions fromthe siteof injection, aswas
observed 40 days postimplantation (marmoset 4) (Fig. 3D). The
double staining for MBP indicated that the GFP-labeled hiPSC-
derived OPCs differentiated into myelin-producing cells (Fig.
4A). We performed costaining for MBP and NF as well as for
MBP and GFP in subsequent serial sections (Fig. 4A) at 40 days af-
ter implantation (marmoset 4) and revealed interaction between
the axons in the corpus callosum and the grafted hiPSC-derived
OPCs (Fig. 4C). Costaining for MBP and STEM121 (human cyto-
plasmic marker) indicated that the hiPSC-derived OPCs differen-
tiated into myelin-producing cells (Fig. 4B). PDGFRa-GFP and
Olig2-GFP double immunostaining at 40 days postimplantation
showed that a substantial number of oligodendrocyte progeni-
tors, along with MBP/GFP positive cells, resided in the corpus
callosum (Fig. 4D; supplemental online Fig. 7C). However, after
40 days, a portion of PDGFRa-GFP positive cells could still be de-
tected at the site of injection (supplemental online Fig. 7A, 7B).
The presence of a few GFAP-GFP double-positive cells indicated
that astrocyte-like cellsmayhave differentiated from the injected
hiPSC-derived OPCs or may have contaminated the cell graft (Fig.
4D). Iba-1 and Mac2 immunostaining revealed the accumulation
of microglia/macrophages around hiPSC-derived OPCs without
compromising their viability (supplemental online Fig. 8A, 8B).
Quantification for PDGFRa-, GFAP-, MBP-, and Olig2-positive im-
planted (GFP+) cells in one standard area within the corpus cal-
losum revealed that most cells express OPC markers or have
developed into mature MBP-positive cells (60%) 40 days after
implantation.
To examine whether the implanted hiPSC-derived OPCs were
capable of forming myelin sheets around axons in the lesions
40 days after implantation, we performed transmission electron
microcopy. Tto identify the implanted cells in the EM sections,
we performed 3,39-diaminobenzidine-intensified immunostaining
for GFP resulting in a clear, dark, very specific electron-dense pre-
cipitate in the entire cytoplasmunder the EMmicroscope (Fig. 5A).
Figure 5B shows in detail a GFP-positive (grafted) oligodendrocyte
that wraps its extensions around a neighboring axon (indicated
with a different color) in the lesion, forming a thin myelin sheet.
DISCUSSION
Human iPSC-derived OPCs have previously been shown to induce
widespread and complete remyelination after transplantation in-
to a mouse mutant (shiverer) that mimics human hypomyelinat-
ing leukodystrophies, genetic disorders in which myelin is not
formed properly [9, 10]. Moreover, human iPSC-derived OPCs
appeared capable of repairing radiation-induced myelin damage
like thatoccurring in theclinicasasideeffectof radiationtherapy for
pediatric brain cancers [12]. The relevance of both clinical applica-
tions for iPSC-derived OPCs may be considered limited. Genetic
hypomyelinating leukodystrophies, such as Pelizaeus-Merzbacher
disease, are rare [23], and for an effective treatment, autologous
iPSC-derived OPCs (after gene correction) have to be administered
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intrauterinely to successfully compete with the endogenous, af-
fected, OPCs to produce normal myelin. Clinical application of au-
tologous iPSC-derived OPCs after brain irradiation is relevant only
in very young cancer patients, ,0.5 years of age, when dividing
OPCs, vulnerable to irradiation, may still be present.
However, the most common demyelinating disorder (inci-
dence 1:1,000 inWestern societies) and as such themost relevant
target for an autologous iPSC-derived OPC transplantation
therapy is MS. In the current nonhuman primate study we have
shown for the first time that intracerebrally implanted human
iPSC-derivedOPCs survive for at least 40 days, albeit under immu-
nosuppression with cyclosporine A, that they selectively migrate
to MS-like lesions and are capable of initiating remyelination of
denuded axons within the inflammatory conditions of these le-
sions. Our marmoset EAE model is generally considered the ani-
mal model that most closely mimics the secondary progressive
Figure 2. Marmoset EAEmodel. (A): Clinical score (right y axis) for EAE progression afterMOG/IFA immunization, combinedwith body weight
(left y axis, dotted line) in fourmarmosets. (B): Luxol fast blue staining reveals demyelinated lesionswithin the corpus callosum. Scale bars: 7mm
(overview), 1 mm and 500mm (magnifications). (C, D): Neurofilament/MBP double immunostaining of a marmoset EAE brain section reveals a
large lesion in the left corpus callosum; areas indicated by squares are further analyzed in C and D. (E): Immunostaining of the lesioned corpus
callosum in the marmoset EAE brain shows morphologic changes in GFAP-positive astrocytes, absence of PDGFRa-positive cells; loss of the
myelin sheath (less MBP staining) results in the increased visibility of neurofilament-positive axons. Scale bars: 50 mm. Abbreviations: EAE,
experimental autoimmuneencephalomyelitis; GFAP, glial fibrillary acidic protein; IFA, incomplete Freund’s adjuvant;MBP,myelin basic protein;
MOG, myelin oligodendrocyte glycoprotein.
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stage ofMS in clinical and pathological presentation. The applica-
tion of iPSC-derived OPCs is particularly relevant for MS patients
in the secondary progressive stage, when endogenous OPCs are
no longer able to remyelinate and rescue damaged axons and so
prevent retrograde, irreversible neuronal degeneration. It is the
most debilitating stage of the disease, for which no therapeutic
treatment is yet available. We have injected iPSC-derived OPCs
into the EAEmarmosets during an early phasewith functional en-
dogenous OPCs still present. Moreover, because of the limited
number of monkeys in this study, their outbred nature, the small
stereotactically injected cell grafts, the relatively short posttrans-
plantation period (because of animal care legislation imposed
Figure 3. Implantation of human iPSC-derived OPCs in EAEmarmosets. (A): Experimental setup for the implantation studies with human iPSC-
derived OPCs in the marmoset EAE model. (B): Episomal GFP-transfected human iPSC-derived OPCs for implantation. Scale bar: 100 mm. (C):
Cresyl violet and Luxol fast blue staining overview at 20 and 40 days after implantation depict themigration pattern of implanted cells in the EAE
marmoset brain. Scale bars: 7 and 6 mm (whole brain) and 1 mm (magnification). (D): Analysis of two parallel sections, taken at a 320-mm in-
terval, shows that GFP-labeled implanted cells migrate across the corpus callosum in both lateral and anterior/posterior directions. Scale bar:
2 mm (whole brain) and 250 mm (magnification). (E): Quantification of GFP-labeled implanted cells at a standard distance from the site of in-
jection reveal the time-dependent pattern of migration (3, 20, 30, and 40 days) (n = 4, mean6 SEM, one-way analysis of variance; p, p, .05;
pp, p , .01; ppp, p , .001). Abbreviations: CC, corpus callosum; EAE, experimental autoimmune encephalomyelitis; GFP, green fluorescent
protein; iPSC, induced pluripotent stem cell; MOG, myelin oligodendrocyte glycoprotein; OPC, oligodendrocyte precursor cell.
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Figure 4. Analysis of hiPSC-derived OPCs in EAE marmosets. (A): GFP/MBP double immunostaining indicates that the implanted cells are
capable of producingmyelin. Scale bars: 25mm. (B): STEM121/MBP double immunostaining indicates that the implanted cells are capable of
producingmyelin. Scale bars: 25mm. (C): Neurofilament/MBP double immunostaining in the same area shows the close interaction ofMBP-
expressing implanted cells with unmyelinated axons. (D): Likewise, GFP/PDGFRa immunostaining reveals immature OPCs (arrows) among
the implanted cells as well as a few GFP/GFAP double-stained cells (arrows), suggesting differentiation of the implanted cells toward astro-
cytes. Scale bars: 50 mm. (E): Scheme indicating the order of subsequent marmoset brain sections used for immunohistochemical analyses
and electron microscopy studies. Quantification of PDGFRa-, GFAP-, MBP-, and Olig2-positive implanted (GFP+) cells in one standard area
within the corpus callosum at 40 days after implantation indicates that the majority of implanted cells became MBP-positive oligodendro-
cytes. Data presented as mean6 SEM. Abbreviations: EAE, experimental autoimmune encephalomyelitis; EM, standard error of the mean;
GFAP, glial fibrillary acidic protein; GFP, green fluorescent protein; hiPSC, human induced pluripotent stem cell; MBP, myelin basic protein;
NF, neurofilament; OPC, oligodendrocyte precursor cell, PDGFRa, platelet-derived growth factor receptor-a.
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restrictions) and the usage of cyclosporine A, firm conclusions
about the consequences of iPSC-derived OPC transplantation
for clinical improvement could not be drawn as yet. Nevertheless,
extrapolation of the beneficial effect of the iPSC-derivedOPCsob-
served in the mouse EAE model to the EAE model in marmosets,
warrants the assumption that under comparable experimental
conditions a clinical effect is likely.
Previous studies have shown that rodent NSCs and OPCs pro-
duce a variety of immunomodulatory, anti-inflammatory, and
neurotrophic factors, responsible for a significant reduction in
clinical scores in EAE animals after intraventricular or intravenous
injection [20, 22, 24–27]. In addition, neuroprotective effects of
the secretome of NSCs have been demonstrated after spinal cord
injury in mice [21] and after intracerebellar injection of NSCs in
mouse models of Machado-Joseph disease [28]. The responsible
factors in the secretomeofNSCs andOPCs have been determined
[22, 29–31]. Also in this study, human iPSC-derivedOPCs appeared
to express a similar set of factors and were able to reduce the EAE
clinical score in mice after intraventricular injection, mainly by re-
ducing cell infiltration and lesion size. In particular, leukemia inhib-
itory factor (LIF) secreted by mouse NSCs or OPCs has been
proposed as playing a crucial neuroprotective and inflammation
suppressive role in the EAE mouse model [32, 33]. However, our
analyses show that LIF production by human NSCs and human
OPCs, in contrast to mouse NSCs and human OPCs, is only at a
low basic level, suggesting that other factors secreted by human
Figure5. Electronmicroscopyof implanted human iPSC-derivedOPCs in EAEmarmosets. (A):Electronmicrograph analysis of implanted hiPSC-
derived OPCs (red arrows) in EAE marmoset brain based on DAB-intensified electron-dense GFP staining. (B): DAB-intensified electron-dense
GFP-labeled oligodendrocytes myelinate multiple axons in the EAE lesion in the marmoset brain (blue, nucleus; green, cytoplasm). Scale bars:
500 nm.Abbreviations: DAB, 3,39-diaminobenzidine; EAE, experimental autoimmune encephalomyelitis; GFP, green fluorescent protein; hiPSC,
human induced pluripotent stem cell; OPC, oligodendrocyte precursor cell; +Ve, positive; –Ve, negative.
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OPCsmight play amore prominent neuroprotective role. The local
stereotactical injectionof human iPSC-derivedOPCs in themarmo-
set cortex did not provoke a reduction in clinical scores,most likely
because of only a very limited, local diffusion of the effectors (in
contrast to the more systemic intraventricular or intravenous ad-
ministration in EAE mice).
CONCLUSION
Ourresults showfor the first timeefficacious remyelinationofhiPSC-
derivedOPCs inprimateswithMS-likedisease,which represents the
closestpossibleapproximation to thehumansituation.Although the
resultsareveryencouraging, theyalso immediatelypoint torequired
follow-up experiments addressing the optimal mode of administra-
tionthatwill allowmigrationofsufficienthiPSC-derivedOPCstomul-
tiple lesion sites. Some of these sites may be less accessible, e.g.,
when theyare clinically silent,withonly a lowreleaseof chemotactic
factors attracting the implanted iPSC-derivedOPCs and/or enclosed
by an astrocytic scar. In view of the current safe possibilities to ge-
netically modify human iPSC-derived cells, the hiPSC-derived OPCs
may be equipped with additional chemokine receptors and/or en-
zymes that degrade the astrocytic scar. Long-term studieswill be es-
sential to determine the safety and stability of grafted iPSC-derived
OPCs. Moreover, it will be interesting to evaluate whether remyeli-
nationcapacityand immunemodulationbyhiPSC-derivedOPCsmay
be of therapeutic use for primary progressive MS.
Some concernmay exist about the safe, large-scale production
of autologous iPSCs and iPSC-derived OPCs and the time and costs
associated with it. The wide-scale implementation of haplotype-
based banking of readily available,well-characterizedhuman iPSCs
(fulfilling cGMP criteria) for transplantation, may eventually obso-
lete the need to generate iPSC lines for each individual MS patient
[34, 35]. Moreover, recent improvements in the protocol for the
differentiation of human iPSCs into OPCs have led to a significant
reduction in the duration of this procedure [36, 37]. Finally, in a
recent report, Rao and Atala have proposed important steps to re-
duce the costs for iPSC production significantly [38].
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